NOS3 and pulmonary hypertension: Likewise, NOS3 variants that alter nitric oxide bioavailability can influence pulmonary vascular resistance and alveolar growth; experimental eNOS deficiency results in pulmonary hypertension, defective alveolarization, and neonatal respiratory failure [51,55].